+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hormonal Contraceptives Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4987017
UP TO OFF until Sep 30th 2023

Primary driving factors for the growth of hormonal contraceptives market are increasing focus on family planning among the people and continuous support from the government. Furthermore, advancements in hormonal contraception such as the advent of hormonal patches, implants and other innovative drug-device combination products are fuelling the market growth. Moreover, the need for preventing unintended pregnancy, urbanization coupled with user awareness is projected to boost the market growth over the forecast period. According to the World Health Organization (WHO), about 74 million women in low and middle-income countries have unintended pregnancies annually, leading to 25 million unsafe abortions and 47000 maternal deaths.

In addition, companies efforts in producing the innovative hormonal contraceptives with fewer side effects and enhanced efficiency anticipated boosting the usage of hormonal contraceptives in the near future. However, side effects associated with the usage of hormonal contraceptives and availability hormone-free contraceptives may hamper the market growth.

Key Market Trends

Contraceptive Pills Expected to Have Significant Share

In the product segment, contraceptive hormonal pills are expected to have significant share owing to ease of use and availability. Moreover, the availability of pipeline products and their expected commercialization anticipated to boost the segment growth furthermore. Combination hormonal contraceptives are anticipated to have a notable market share due to their better efficiency and success rate in preventing pregnancy. In addition, companies focus on new product launches and advancing the combination hormonal contraceptives may bolster the segment growth. Intrauterine devices anticipated to have notable growth rate due to adaptation of long-acting contraception devices couple with efficiency.

Moreover, the increasing research and development investments and product pipelines in hormonal contraception and new product launch expected to boost the overall market growth.

North America Expected to have Significant Market Share

Owing to the high adoption of hormonal contraceptives, well-established healthcare infrastructure and presence of key market players in the region, North America hormonal contraceptives market is expected to grow at significant rates. According to the Center for Disease Control and Prevention (CDC), in 2015-2017, 72.2 million US woman aged between 19-49 were using contraceptives. In addition, government initiatives in increasing awareness regarding birth control and growing affordability fueling the market growth.

The developed countries in Europe such as United Kingdom and Germany are having well-established healthcare infrastructure and high awareness regarding hormonal contraception which is expected to boost regional growth. The Asia-Pacific region is projected to have considerable growth rate owing to developing healthcare infrastructure and availability of a large pool of population using contraception.

Competitive Landscape

Global hormonal contraceptives market is moderately fragmented and competitive. Market players are focusing on product innovations, new product launches and regional expansions to increase their market share. The key market players operating in clot management devices market include Allergan plc, Afaxys, Inc., Merck & Co., Inc., Pfizer, and Mylan N.V. among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Focus on Family Planning and Favorable Regulations by Government
4.2.2 Advancements in Hormonal Contraception
4.3 Market Restraints
4.3.1 Availability of Alternative Contraceptive Methods
4.3.2 Health Risks Associated With Hormonal Contraception
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product
5.1.1 Oral Contraceptives
5.1.2 Skin Patches
5.1.3 Intrauterine Devices
5.1.4 Hormonal Implants
5.1.5 Others
5.2 By Hormone
5.2.1 Progestin Only
5.2.2 Combined Hormone Contraceptives
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Allergan plc
6.1.2 Afaxys, Inc.
6.1.3 Merck & Co., Inc.
6.1.4 Pfizer Inc.
6.1.5 Mylan N.v.
6.1.6 Bayer AG
6.1.7 Agile Therapeutics
6.1.8 Novartis AG
6.1.9 Johnson & Johnson
6.1.10 The Piramal Group

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergan plc
  • Afaxys, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Mylan N.v.
  • Bayer AG
  • Agile Therapeutics
  • Novartis AG
  • Johnson & Johnson
  • The Piramal Group